ArticleEuropean heart journal open2026
Cardiac magnetic resonance T1 mapping predicts outcome in patients with a systemic right ventricle:
Article in European heart journal open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: In patients with a systemic right ventricle (sRV), the sRV is faced with an increased afterload compared to a right ventricle in sub-pulmonary position, leading to the development of fibrosis followed by ventricular dysfunction. Cardiac magnetic resonance (CMR) T1 mapping (T1) and its derived parameter, such as the extracellular volume (ECV), allow quantification of interstitial fibrosis. The SERVE study, a multicentric, placebo-controlled trial evaluated the effect of tadalafil in sRV patients. The aim of this sub-analysis of the SERVE trial was to evaluate (i) the relationship between T1 mapping parameters and the clinical composite endpoint of hospitalization for heart failure, clinically relevant arrhythmias, and all-cause mortality and (ii) their evolution over time, their correlation with CMR functional parameters, and the impact of study treatment. Methods and results: Patients included in the SERVE trial underwent a 1.5T CMR at baseline and at 1- and 3-year follow-up. For each CMR exam, native and post-contrast T1, as well as ECV, were calculated. In addition, late gadolinium enhancement (LGE) imaging was performed. Cardiac magnetic resonance was available for 60 patients. Native sRV T1 and ECV above the 75th percentile, but not LGE, were associated with the clinical composite endpoint. There was no significant change and no influence of tadalafil treatment on sRV T1 and ECV. Conclusion: T1 mapping as a non-invasive biomarker of the degree of myocardial fibrosis predicts outcome in patients with sRV and should be incorporated in risk stratification in these patients. The phosphodiesterase-5 inhibitor tadalafil appears to have no impact on the development of interstitial or macroscopic fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.